Drug Profile


Alternative Names: Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck; MSB-0010718C; PF-06834635

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer EMD Serono; Merck KGaA; National Cancer Institute (USA); Pfizer; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Merkel cell carcinoma
  • Phase III Breast cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Nasopharyngeal cancer; Recurrent respiratory papillomatosis
  • Phase I Hodgkin's disease; Solid tumours
  • Preclinical Acute myeloid leukaemia; Diffuse large B cell lymphoma; Endometrial cancer
  • Phase Unknown Glioblastoma; Intestinal cancer

Most Recent Events

  • 26 Dec 2016 Vanderbilt-Ingram Cancer Center, National Cancer Institute and EMD Serono plan a phase II trial for Intestinal cancer (Monotherapy, Metastatic disease, Late-stage disease) in USA (NCT03000179)
  • 22 Dec 2016 St. Jude Children's Research Hospital in collaboration with National Cancer Institute plans a phase II trial for Osteosarcoma in USA (NCT03006848)
  • 20 Dec 2016 Groupe Oncologie Radiotherapie Tete et Cou,Merck Sharp & Dohme and Pfizer plan the phase III REACH trial for Head and neck cancer (Combination therapy, First-line therapy, Late-stage disease) in France (IV, Infusion) (NCT02999087)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top